Amifampridine, also known as Firdapse or aimipyridine phosphate, is developed and produced by BioMarin in the United States. It is a special drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The main ingredient of amifampridine is amifampridine, which blocks potassium channels, improves neuromuscular conduction, and relieves the muscle weakness symptoms of LEMS patients.

What is amifampridine?

Amifampridine was developed and produced by BioMarin in the United States and was approved for marketing by the European EMA on December 23, 2009.

Basic information about the drug

The original specification of amifampridine is 10mg×100 tablets, and the price is relatively high, about US$3,270 per box. Aimipyridine is sold in many countries around the world, but it has not yet been launched in China and has not entered China's medical insurance. There are currently no generic drugs for amifampridine on the market, and patients need to purchase them through regular medical service institutions.

Drug ingredients and dosage forms

The main ingredient of Firdapse is amifampridine, and the dosage form is tablets. The tablets are white to off-white, round, and display functional scores. Each tablet is engraved with a specific mark for patients to identify. Amifampridine tablets contain 10 mg of Amifampridine, but Amifampridine is not its active ingredient, but exists as an excipient.

Precautions for the use of amifampridine

Amifenpyridine may cause a series of adverse reactions during treatment. The following are matters that need to be paid attention to when using amifampridine:

Adverse reactions

The most common adverse reactions include paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. For patients with adverse reactions, the dose should be adjusted or the drug should be discontinued in time, and medical consultation should be sought.

Guidance on medication for special populations

For special populations, such as pregnant women and lactating women, the use of amifampridine should be cautious. There is no data on the risk of development associated with the use of amifampridine by pregnant women, and pregnant women should avoid using it. For breastfeeding women, there is currently no data on the effects of amitraz on breastfed infants. It is recommended to avoid use or consult a doctor.

The use of amitraz should strictly follow the doctor's instructions or instructions and be carried out under the guidance of professional medical personnel. During the use of amitraz, patients should regularly monitor liver function and lung conditions to prevent possible adverse reactions. Through scientific and reasonable medication, health conditions can be better managed and the quality of life can be improved.